@article{JTD26164,
author = {Byeong-Ho Jeong and Sang-Won Um},
title = {Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {1},
year = {2018},
keywords = {},
abstract = {Osimertinib (Tagrisso, AstraZeneca) is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and irreversibly inhibits EGFR-TKI sensitizing mutations and the T790M mutation; the drug exhibits lower-level activity against wild-type EGFR (1). Recently, the AME Lung Cancer Collaborative Group summarized the current role of osimertinib and made recommendations as to how osimertinib could,},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/26164}
}